NCT05593562View on ClinicalTrials.gov

Study on Human Mass Balance of SPH3127 Tablets

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 16, 2022

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Primary Mild and Moderate Hypertension
Interventions
DRUG

SPH3127

Oral 100 mg \[14 c\] SPH3127 mixed suspension

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY